Results for the substance zanubrutinib

Zanubrutinib is a medication used to treat certain types of hematologic cancers, such as mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), and chronic lymphocytic leukemia (CLL). It is a selective inhibitor of Bruton’s tyrosine kinase (BTK), an enzyme essential for the survival and proliferation of malignant B cells.

The mechanism of action of zanubrutinib involves irreversibly binding to BTK, thereby blocking the signaling required for B-cell activation and survival. By inhibiting this enzyme, zanubrutinib reduces the growth and spread of cancerous B cells, making it effective in treating lymphomas and leukemias involving B cells.

Zanubrutinib is administered orally, usually in capsule form, twice daily or as directed by a doctor. It is used either as monotherapy or in combination with other medications, depending on the type and stage of the disease. Treatment is tailored to each patient, and the response to therapy is monitored regularly.

While effective, zanubrutinib may cause side effects. The most common include fatigue, diarrhea, upper respiratory tract infections, minor bleeding, nausea, and skin rashes. In rare cases, more serious reactions such as atrial fibrillation, severe infections, or cytopenias (reduction in blood cell counts) may occur. Close monitoring of patients during treatment is essential to detect and manage potential complications promptly.